Latest & greatest articles for furosemide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on furosemide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on furosemide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for furosemide

1. Torsemide versus furosemide in chronic heart failure: a systematic review and meta-analysis

Torsemide versus furosemide in chronic heart failure: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

2. Efficacy of furosemide for treatment of cirrhosis: a systematic review protocol of randomized controlled trials

Efficacy of furosemide for treatment of cirrhosis: a systematic review protocol of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

3. Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight

Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight To evaluate the association between furosemide exposure and patent ductus arteriosus (PDA) in a large, contemporary cohort of hospitalized infants with very low birth weight (VLBW).Using the Pediatrix Medical Group Clinical Data Warehouse, we identified all inborn infants of VLBW <37 weeks of gestation discharged from the neonatal intensive care unit after the first postnatal (...) to mechanical ventilation and inotropes. Furosemide was prescribed to 4055 (9%) infants. On multivariable regression, exposure to furosemide was associated with decreased odds of PDA treatment (OR 0.72; 95% CI 0.65-0.79). Increasing percentage of days with furosemide exposure was not associated with PDA treatment (OR 1.01; 95% CI 0.97-1.06).Furosemide exposure was not associated with increased odds of PDA treatment in hospitalized infants of VLBW. Further studies are needed to characterize the efficacy

2018 EvidenceUpdates

4. Furosemide

Furosemide Top results for furosemide - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for furosemide The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

6. Temporal bone histopathology of furosemide ototoxicity (PubMed)

Temporal bone histopathology of furosemide ototoxicity To describe the human temporal bone pathology in two patients who incurred furosemide induced ototoxicity.1) A 46-year-old woman in acute liver and renal failure treated with high doses of furosemide for anasarca who developed a rapidly progressive severe-to-profound asymmetric sensorineural hearing loss. 2) A 65-year-old woman with undifferentiated small cell carcinoma of the lung who received intravenous furosemide 1 day prior to death (...) for pulmonary edema.Removal of temporal bones, histologic processing, and light microscopy of temporal bones.Temporal bone histopathology and correlation with clinical and audiometric data.All three temporal bones demonstrated edema and cystic changes in the stria vascularis. In the first case the furosemide exposure was associated with hearing loss and the pathological changes were more extensive including cystic changes in the Hensen's cells, collapse of Reissner's membrane and the tectorial membrane

Full Text available with Trip Pro

2017 Laryngoscope investigative otolaryngology

7. Peritoneal Dialysis vs Furosemide for Prevention of Fluid Overload in Infants After Cardiac Surgery: A Randomized Clinical Trial

Peritoneal Dialysis vs Furosemide for Prevention of Fluid Overload in Infants After Cardiac Surgery: A Randomized Clinical Trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2017 PedsCCM Evidence-Based Journal Club

8. What are the effects of hypertonic saline plus furosemide in acute heart failure?

What are the effects of hypertonic saline plus furosemide in acute heart failure? In search of new therapies to solve diuretic resistance in acute heart failure, the addition of hypertonic saline has been proposed. Searching in Epistemonikos database, which is maintained by screening 30 databases, we identified two systematic reviews including nine pertinent randomized controlled trials. We combined the evidence and generated a summary of findings following the GRADE approach. We concluded (...) hypertonic saline associated with furosemide probably decrease mortality, length of hospital stay and hospital readmission in patients with acute decompensated heart failure.

Full Text available with Trip Pro

2016 Medwave

9. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. (PubMed)

Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. Loop diuretics are first-line medications for congestive heart failure (CHF); however, they are associated with serious adverse effects, including decreased renal function, and sympathetic nervous and renin-angiotensin system activation. We tested whether tolvaptan, a vasopressin V2-receptor antagonist, could reduce unfavourable furosemide-induced effects during CHF (...) treatment.Sixty patients emergently hospitalized owing to CHF-induced dyspnea were randomly assigned to receive either 40 mg intravenous furosemide daily or 7.5 mg oral tolvaptan for 5 days after admission. Both groups also received intravenous carperitide and canrenoate potassium. As results, baseline patient characteristics were similar between the furosemide (n = 30) and the tolvaptan (n = 30) groups, with no significant difference in 5 day urine volume or fluid balance. Brain natriuretic peptide and body

Full Text available with Trip Pro

2016 ESC heart failure Controlled trial quality: uncertain

10. Comparison of Intraoperative Aminophylline Versus Furosemide in Treatment of Oliguria During Pediatric Cardiac Surgery

Comparison of Intraoperative Aminophylline Versus Furosemide in Treatment of Oliguria During Pediatric Cardiac Surgery PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2016 PedsCCM Evidence-Based Journal Club

11. Furosemide sc2Wear micro-pump patch for oedema in heart failure

Furosemide sc2Wear micro-pump patch for oedema in heart failure Furosemide sc2Wear micro-pump patch for oedema in heart failure Furosemide sc2Wear micro-pump patch for oedema in heart failure NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Furosemide sc2Wear micro-pump patch for oedema in heart failure. Birmingham: NIHR Horizon Scanning (...) and surrounding tissue. Furosemide sc2Wear micro-pump patch is intended to treat patients with heart failure who have increased fluid in their lungs and other tissues. This treatment aims to reduce hospital stay for patients who suffer a worsening of their heart failure. The sc2Wear micro-pump delivers the drug just under the skin by a wearable patch, rather than requiring hospital treatment where drugs are given directly into the blood by a drip. If furosemide sc2Wear micro-pump is licensed for use in the UK

2016 Health Technology Assessment (HTA) Database.

12. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial (PubMed)

Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial Contrast-induced nephropathy is common in patients with coronary angiography. Mechanistically, forced euvolemic diuresis with mannitol and furosemide ought to prevent contrast-induced nephropathy. Our objectives are to: (1) undertake a randomized trial testing this hypothesis, and (2) conduct a meta-analysis (...) of our findings with 2 earlier studies.(1) Randomized allocation-concealed controlled trial with blinded ascertainment of outcomes, and (2) random-effects meta-analysis of 3 trials.Single-center study of consenting adults with serum creatinine level greater than 1.7 mg/dL undergoing coronary angiography; patients unable to tolerate fluid challenge or receiving dialysis were excluded. Two previous trials had randomly assigned 159 patients.Forced euvolemic diuresis with saline, mannitol, and furosemide

2010 EvidenceUpdates Controlled trial quality: predicted high

13. High dose furosemide plus small volume hypertonic saline solutions (HSS) vs repeated paracentesis as treatment of refractory ascites: a randomized pilot study (PubMed)

High dose furosemide plus small volume hypertonic saline solutions (HSS) vs repeated paracentesis as treatment of refractory ascites: a randomized pilot study In patients with cirrhosis, ascites is defined as refractory when it cannot be mobilized or recurs early in standard diuretic therapy.To compare the safety and efficacy of intravenous high-dose furosemide + hypertonic saline solutions (HSS) with repeated paracentesis in patients with cirrhosis and refractory ascites.Eighty-four subjects (...) (59/25 M/F) with cirrhosis, mostly of viral aetiology, admitted for refractory ascites, were randomly assigned to receive furosemide (250-1000 mg/bid i.v.) plus HSS (150 mL H(2)O with NaCl 1.4-4.6% or 239-187 mEq/L) (60 patients, Group A) or to repeated paracentesis and a standard diuretic schedule (24 patients, Group B).During hospitalization, Group A patients had more diuresis (1605 +/- 131 mL vs. 532 +/- 124 mL than Group B patients; P < 0.001) and a greater loss of weight at discharge (-8.8

Full Text available with Trip Pro

2009 EvidenceUpdates Controlled trial quality: uncertain

14. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. (PubMed)

Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Although primary hyperparathyroidism is the most common cause of hypercalcemia, cancer is the most common cause requiring inpatient intervention. An estimated 10% to 20% of all patients with cancer have hypercalcemia at some point in their disease trajectory, particularly in advanced disease. Aggressive saline hydration and varying doses of furosemide continue to be the standard of care for emergency management (...) . However, a review of the evidence for the use of furosemide in the medical management of hypercalcemia yields only case reports published before the introduction of bisphosphonates, in contrast to multiple randomized, controlled trials supporting the use of bisphosphonates. The use of furosemide in the management of hypercalcemia should no longer be recommended.

2008 Annals of Internal Medicine

15. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury

A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2008 PedsCCM Evidence-Based Journal Club

16. Narrative review: furosemide for hypercalcemia. An unproven yet common practice

Narrative review: furosemide for hypercalcemia. An unproven yet common practice Narrative review: furosemide for hypercalcemia. An unproven yet common practice Narrative review: furosemide for hypercalcemia. An unproven yet common practice LeGrand S B, Leskuski D, Zama I CRD summary This review concluded that evidence does not support the use of furosemide in common practice as the primary treatment of hypercalcaemia of any cause. Given several limitations with the included studies and review (...) , including small sample size, indirect treatment comparisons and potential bias, and the paucity of current evidence, the authors' conclusions should be interpreted with extreme caution. Authors' objectives To examine the evidence on the use of furosemide as the primary therapy for hypercalcaemia. Searching MEDLINE (1950 to April 2008), the American College of Physicians Journal Club, the Cochrane Database of Systematic Reviews and DARE were searched for articles in English; articles in French were also

2008 DARE.

17. Nebulized furosemide for the management of dyspnea: does the evidence support its use?

Nebulized furosemide for the management of dyspnea: does the evidence support its use? Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

18. Albumin and furosemide for acute lung injury (PubMed)

Albumin and furosemide for acute lung injury Albumin and furosemide for acute lung injury | Critical Care | Full Text Advertisement Menu Search Search all BMC articles Search Menu Table of Contents , Eric B Milbrandt and Ramesh Venkataraman Critical Care 2007 11 :314 © BioMed Central Ltd 2007 Published: 27 September 2007 Citation Martin GS, Moss M, Wheeler AP, Mealer M, Morris JA, Bernard GR: A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients (...) with acute lung injury. Crit Care Med 2005, 33:1681–1687 [ ]. Background Hypoproteinemia is a common condition in critically ill patients, associated with the development of acute lung injury and acute respiratory distress syndrome and subsequent worse clinical outcomes. Albumin with furosemide benefits lung physiology in hypoproteinemic patients with acute lung injury/acute respiratory distress syndrome, but the independent pharmacologic effects of these drugs are unknown. Methods Objective To determine

Full Text available with Trip Pro

2007 Critical Care - EBM Journal Club

19. Drugs - Furosemide (Frusemide, Lasix)

Drugs - Furosemide (Frusemide, Lasix) Furosemide (Frusemide, Lasix) FRM Drugs October 2006 Page 1 of 1 Drugs PRESENTATION Ampoules containing furosemide 50 milligrams/5ml. OR Ampoules containing furosemide 40 milligrams/2ml. OR Pre-?lled syringe containing furosemide 80 milligrams. ACTIONS Furosemide is a potent diuretic with a rapid onset (within 30 minutes) and short duration. DOSAGE AND ADMINISTRATION Route: IV ADDITIONAL INFORMATION Nitrates are the first line treatment for acute pulmonary (...) oedema. Use furosemide secondary to nitrates in the treatment of acute pulmonary oedema where transfer times to hospital are prolonged. CAUTIONS Hypokalaemia (low potassium) could induce arrhythmias. Pregnancy. INDICATIONS Pulmonary oedema secondary to Left Ventricular failure (LVF). CONTRA-INDICATIONS Pre-comatose state secondary to liver cirrhosis, severe renal failure with anuria. Children <16 years. SIDE EFFECTS Hypotension. Gastro-intestinal disturbances. Administer SLOWL Y over 2 minutes. AGE

2007 Joint Royal Colleges Ambulance Liaison Committee

20. Furosemide (Frusemide, Lasix)

Furosemide (Frusemide, Lasix) Furosemide (Frusemide, Lasix) FRM Drugs October 2006 Page 1 of 1 Drugs PRESENTATION Ampoules containing furosemide 50 milligrams/5ml. OR Ampoules containing furosemide 40 milligrams/2ml. OR Pre-?lled syringe containing furosemide 80 milligrams. ACTIONS Furosemide is a potent diuretic with a rapid onset (within 30 minutes) and short duration. DOSAGE AND ADMINISTRATION Route: IV ADDITIONAL INFORMATION Nitrates are the first line treatment for acute pulmonary oedema (...) . Use furosemide secondary to nitrates in the treatment of acute pulmonary oedema where transfer times to hospital are prolonged. CAUTIONS Hypokalaemia (low potassium) could induce arrhythmias. Pregnancy. INDICATIONS Pulmonary oedema secondary to Left Ventricular failure (LVF). CONTRA-INDICATIONS Pre-comatose state secondary to liver cirrhosis, severe renal failure with anuria. Children <16 years. SIDE EFFECTS Hypotension. Gastro-intestinal disturbances. Administer SLOWL Y over 2 minutes. AGE DOSE

2006 Joint Royal Colleges Ambulance Liaison Committee